Clinical Pharmacokinetics

, Volume 50, Issue 2, pp 81–98 | Cite as

Clinical Pharmacokinetics of Metformin

  • Garry G. Graham
  • Jeroen Punt
  • Manit Arora
  • Richard O. Day
  • Matthew P. Doogue
  • Janna Duong
  • Timothy J. Furlong
  • Jerry R. Greenfield
  • Louise C. Greenup
  • Carl M. Kirkpatrick
  • John E. Ray
  • Peter Timmins
  • Kenneth M. Williams
Review Article

Abstract

Metformin is widely used for the treatment of type 2 diabetes mellitus. It is a biguanide developed from galegine, a guanidine derivative found in Galega officinalis (French lilac). Chemically, it is a hydrophilic base which exists at physiological pH as the cationic species (>99.9%). Consequently, its passive diffusion through cell membranes should be very limited. The mean ± SD fractional oral bioavailability (F) of metformin is 55 ± 16%. It is absorbed predominately from the small intestine.

Metformin is excreted unchanged in urine. The elimination half-life (t1/2) of metformin during multiple dosages in patients with good renal function is approximately 5 hours. From published data on the pharmacokinetics of metformin, the population mean of its clearances were calculated. The population mean renal clearance (CLR) and apparent total clearance after oral administration (CL/F) of metformin were estimated to be 510 ± 130 mL/min and 1140 ± 330 mL/min, respectively, in healthy subjects and diabetic patients with good renal function. Over a range of renal function, the population mean values of CLR and CL/F of metformin are 4.3 ± 1.5 and 10.7 ± 3.5 times as great, respectively, as the clearance of creatinine (CLCR). AS the CLR and CL/F decrease approximately in proportion to CLCR, the dosage of metformin should be reduced in patients with renal impairment in proportion to the reduced CLCR.

The oral absorption, hepatic uptake and renal excretion of metformin are mediated very largely by organic cation transporters (OCTs). An intron variant of OCT1 (single nucleotide polymorphism [SNP] rs622342) has been associated with a decreased effect on blood glucose in heterozygotes and a lack of effect of metformin on plasma glucose in homozygotes. An intron variant of multidrug and toxin extrusion transporter [MATE1] (G>A, SNP rs2289669) has also been associated with a small increase in antihyperglycaemic effect of metformin. Overall, the effect of structural variants of OCTs and other cation transporters on the pharmacokinetics of metformin appears small and the subsequent effects on clinical response are also limited. However, intersubject differences in the levels of expression of OCT1 and OCT3 in the liver are very large and may contribute more to the variations in the hepatic uptake and clinical effect of metformin.

Lactic acidosis is the feared adverse effect of the biguanide drugs but its incidence is very low in patients treated with metformin. We suggest that the mean plasma concentrations of metformin over a dosage interval be maintained below 2.5 mg/L in order to minimize the development of this adverse effect.

References

  1. 1.
    Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29: 1963–72PubMedCrossRefGoogle Scholar
  2. 2.
    Clinical Task Force of International Diabetes Federation. Global guideline for type 2 diabetes: recommendations for standard, comprehensive, and minimal care. Diab Med 2006; 23(6): 579–93CrossRefGoogle Scholar
  3. 3.
    Sheiner LB, Benet LZ, Pagliaro LA. A standard approach to compiling clinical pharmacokinetic data. J Pharmacokinet Biopharm 1981; 9: 59–127PubMedCrossRefGoogle Scholar
  4. 4.
    Day RO, Graham GG, Hicks M, et al. Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. Clin Pharmacokinet 2007; 46: 623–44PubMedCrossRefGoogle Scholar
  5. 5.
    Craig PN. Drug compendium. In: Hansch C, Sammes PG, Taylor JB, editors. Comprehensive medicinal chemistry. Oxford: Pergamon Press, 1990: 237–965Google Scholar
  6. 6.
    Clarke GS, Bretnall AE. Metformin hydrochloride. In: Brittain HG, editor. Analytical profiles of drug substances and excipients. San Diego (CA): Academic Press, 1998: 243–84Google Scholar
  7. 7.
    Tucker GT, Casey C, Phillips PJ, et al. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol 1981; 12: 235–46PubMedCrossRefGoogle Scholar
  8. 8.
    Sirtori CR, Franceschini G, Galli-Kienle M, et al. Disposition of metformin (N,N-dimethylbiguanide) in man. Clin Pharmacol Ther 1978; 24: 683–93PubMedGoogle Scholar
  9. 9.
    Pentikäinen PJ, Neuvonen PJ, Penttilä A. Pharmacokinetics of metformin after intravenous and oral administration to man. Eur J Clin Pharmacol 1979; 16: 195–202PubMedCrossRefGoogle Scholar
  10. 10.
    Robert F, Fendri S, Hary L, et al. Kinetics of plasma and erythrocyte metformin after acute administration in healthy subjects. Diabetes Metab 2003; 29: 279–83PubMedCrossRefGoogle Scholar
  11. 11.
    Kennedy M, Chinwah P, Wade DN. A pharmacological method of measuring mouth caecal transit time in man. Br J Clin Pharmacol 1979; 8: 372–3PubMedCrossRefGoogle Scholar
  12. 12.
    Marathe PH, Wen Y, Norton J, et al. Effect of altered gastric emptying and gastrointestinal motility on metformin absorption. Br J Clin Pharmacol 2000; 50: 325–32PubMedCrossRefGoogle Scholar
  13. 13.
    Sambol NC, Brookes LG, Chiang J, et al. Food intake and dosage level, but not tablet vs solution dosage form, affect the absorption of metformin HCl in man. Br J Clin Pharmacol 1996; 42: 510–2PubMedCrossRefGoogle Scholar
  14. 14.
    Marathe PH, Arnold ME, Meeker J, et al. Pharmacokinetics and bioavailability of a metformin/glyburide tablet administered alone and with food. J Clin Pharmacol 2000; 40: 1494–502PubMedGoogle Scholar
  15. 15.
    Karim A, Slater M, Bradford D, et al. Oral antidiabetic drugs: effect of food on absorption of pioglitazone and metformin from a fixed-dose combination tablet. J Clin Pharmacol 2007; 47: 48–55PubMedCrossRefGoogle Scholar
  16. 16.
    He YL, Flannery B, Campestrini J, et al. Effect of food on the pharmacokinetics of a vildagliptin/metformin (50/100 mg) fixed-dose combination tablet in healthy volunteers. Curr Med Res Opin 2008; 24: 1703–9PubMedCrossRefGoogle Scholar
  17. 17.
    Timmins P, Donahue S, Meeker J, et al. Steady-state pharmacokinetics of a novel extended-release metformin formulation. Clin Pharmacokinet 2005; 44: 721–9PubMedCrossRefGoogle Scholar
  18. 18.
    Rao N, Chou T, Ventura D, et al. Investigation of the pharmacokinetic and pharmacodynamic interactions between memantine and glyburide/metformin in healthy young subjects: a single-center, multiple-dose, open-label study. Clin Ther 2005; 27: 1596–606PubMedCrossRefGoogle Scholar
  19. 19.
    Sambol NC, Chiang J, O’Conner M, et al. Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus. J Clin Pharmacol 1996; 36: 1012–21PubMedCrossRefGoogle Scholar
  20. 20.
    Herman GA, Bergman A, Yi B, et al. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when coadministered in patients with type 2 diabetes. Curr Med Res Opin 2006; 22: 1939–47PubMedCrossRefGoogle Scholar
  21. 21.
    Hong Y, Rohatagi S, Habtemariam B, et al. Population exposure-response modeling of metformin in patients with type 2 diabetes mellitus. J Clin Pharmacol 2008; 48: 696–707PubMedCrossRefGoogle Scholar
  22. 22.
    Cullen E, Liao J, Lukacsko P, et al. Pharmacokinetics and dose proportionality of extended-release metformin following administration of 1000, 1500, 2000 and 2500 mg in healthy volunteers. Biopharm Drug Dispos 2004; 25: 261–3PubMedCrossRefGoogle Scholar
  23. 23.
    Schwartz S, Fonseca V, Berner B et al. Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes. Diabetes Care 2006; 29: 759–64PubMedCrossRefGoogle Scholar
  24. 24.
    Davidson J, Howlett H. New prolonged-release metformin improves gastrointestinal tolerabilty. Br J Diab Vasc Dis 2004; 4: 273–7CrossRefGoogle Scholar
  25. 25.
    Feher MD, Al-Mrayat M, Brake J, et al. Tolerability of prolonged-release metformin (Glucophage SR) in individuals intolerant to standard metformin: results from four UK centres. Br J Diab Vasc Dis 2007; 7: 225–8CrossRefGoogle Scholar
  26. 26.
    National Institute for Health and Clinical Excellence. NICE guidance: type 2 diabetes- newer agents (partial update of CG66). London: NICE, 2010 Oct 7 [online]. Available from URL: http://www.nice.org.uk/cg87 [Accessed 2010 Dec 13]
  27. 27.
    Zhou M, Xia L, Wang J. Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine. Drug Metab Dispos 2007; 35: 1956–62PubMedCrossRefGoogle Scholar
  28. 28.
    Choi MK, Song IS. Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet 2008; 23: 243–53PubMedCrossRefGoogle Scholar
  29. 29.
    Hilgendorf C, Ahlin G, Seithel A, et al. Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab Dispos 2007; 35: 1333–40PubMedCrossRefGoogle Scholar
  30. 30.
    Muller J, Lips KS, Metzner L, et al. Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem Pharmacol 2005; 70: 1851–60PubMedCrossRefGoogle Scholar
  31. 31.
    Shu Y, Brown C, Castro RA, et al. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther 2008; 83: 273–80PubMedCrossRefGoogle Scholar
  32. 32.
    Chen L, Pawlikowski B, Schlessinger A, et al. Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin. Pharmacogenet Genomics 2010; 20: 687–99PubMedCrossRefGoogle Scholar
  33. 33.
    Shu Y, Sheardown SA, Brown C, et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 2007; 117: 1422–31PubMedCrossRefGoogle Scholar
  34. 34.
    Zolk O. Current understanding of the pharmacogenomics of metformin. Clin Pharmacol Ther 2009; 86: 595–8PubMedCrossRefGoogle Scholar
  35. 35.
    Tzvetkov MV, Vormfelde SV, Balen D, et al. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther 2009; 86: 299–306PubMedCrossRefGoogle Scholar
  36. 36.
    Chen Y, Li S, Brown C, et al. Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Pharmacogenet Genomics 2009; 19: 497–504PubMedCrossRefGoogle Scholar
  37. 37.
    Song IS, Shin HJ, Shim EJ, et al. Genetic variants of the organic cation transporter 2 influence the disposition of metformin. Clin Pharmacol Ther 2008; 84: 559–62PubMedCrossRefGoogle Scholar
  38. 38.
    Bailey CJ, Wilcock C, Scarpello JH. Metformin and the intestine. Diabetologia 2008; 51: 1552–3PubMedCrossRefGoogle Scholar
  39. 39.
    Bailey CJ, Mynett KJ, Page T. Importance of the intestine as a site of metformin-stimulated glucose utilization. Br J Pharmacol 1994; 112: 671–5PubMedCrossRefGoogle Scholar
  40. 40.
    Proctor WR, Bourdet DL, Thakker DR. Mechanisms underlying saturable intestinal absorption of metformin. Drug Metab Dispos 2008; 36: 1650–8PubMedCrossRefGoogle Scholar
  41. 41.
    Beckmann R. Absorption, distribution in the organism and elimination of metformin. Diabetologia 1969; 5: 318–24PubMedCrossRefGoogle Scholar
  42. 42.
    Wilcock C, Wyre ND, Bailey CJ. Subcellular distribution of metformin in rat liver. J Pharm Pharmacol 1991; 43: 442–4PubMedCrossRefGoogle Scholar
  43. 43.
    Wang DS, Jonker JW, Kato Y, et al. Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther 2002; 302: 510–5PubMedCrossRefGoogle Scholar
  44. 44.
    Nies AT, Koepsell H, Winter S, et al. Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology 2009; 50: 1227–40PubMedCrossRefGoogle Scholar
  45. 45.
    Wang DS, Kusuhara H, Kato Y, et al. Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin. Mol Pharmacol 2003; 63: 844–8PubMedCrossRefGoogle Scholar
  46. 46.
    Sogame Y, Kitamura A, Yabuki M, et al. A comparison of uptake of metformin and phenformin mediated by hOCT1 in human hepatocytes. Bio-pharm Drug Dispos 2009; 30: 476–84CrossRefGoogle Scholar
  47. 47.
    White DL, Saunders VA, Dang P, et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 2007; 110: 4064–72PubMedCrossRefGoogle Scholar
  48. 48.
    Tanihara Y, Masuda S, Sato T, et al. Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol 2007; 74: 359–71PubMedCrossRefGoogle Scholar
  49. 49.
    Otsuka M, Matsumoto T, Morimoto R, et al. A human transporter protein that mediates the final excretion step for toxic organic cations. Proc Natl Acad Sci U S A 2005; 102: 17923–8PubMedCrossRefGoogle Scholar
  50. 50.
    Hawthorne G. Metformin use and diabetic pregnancy-has its time come? Diab Med 2006; 23: 223–7CrossRefGoogle Scholar
  51. 51.
    Nicholson W, Bolen S, Witkop CT, et al. Benefits and risks of oral diabetes agents compared with insulin in women with gestational diabetes: a systematic review. Obstet Gynecol 2009; 113: 193–205PubMedGoogle Scholar
  52. 52.
    Rowan JA, Hague WM, Gao W, et al. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med 2008; 358: 2003–15PubMedCrossRefGoogle Scholar
  53. 53.
    Kovo M, Kogman N, Ovadia O, et al. Carrier-mediated transport of metformin across the human placenta determined by using the ex vivo perfusion of the placental cotyledon model. Prenatal Diagnosis 2008; 28: 544–8PubMedCrossRefGoogle Scholar
  54. 54.
    Hughes RC, Gardiner SJ, Begg EJ, et al. Effect of pregnancy on the pharmacokinetics of metformin. Diab Med 2006; 23: 323–6CrossRefGoogle Scholar
  55. 55.
    Charles B, Norris R, Xiao X, et al. Population pharmacokinetics of metformin in late pregnancy. Ther Drug Monit 2006; 28: 67–72PubMedCrossRefGoogle Scholar
  56. 56.
    Eyal S, Easterling TR, Carr D, et al. Pharmacokinetics of metformin during pregnancy. Drug Metab Dispos 2010; 38: 833–40PubMedCrossRefGoogle Scholar
  57. 57.
    Gardiner SJ, Kirkpatrick CM, Begg EJ, et al. Transfer of metformin into human milk. Clin Pharmacol Ther 2003; 73: 71–7PubMedCrossRefGoogle Scholar
  58. 58.
    Hiasa M, Matsumoto T, Komatsu T, et al. Wide variety of locations for rodent MATE1, a transporter protein that mediates the final excretion step for toxic organic cations. Am J Physiol Cell Physiol 2006; 291: C678–86PubMedCrossRefGoogle Scholar
  59. 59.
    Noel M. Kinetic study of normal and sustained release dosage forms of metformin in normal subjects. Res Clin For 1979; 1: 35–45Google Scholar
  60. 60.
    Sambol NC, Chiang J, Lin ET, et al. Kidney function and age are both predictors of pharmacokinetics of metformin. J Clin Pharmacol 1995; 35: 1094–102PubMedGoogle Scholar
  61. 61.
    Somogyi A, Stockley C, Keal J, et al. Reduction of metformin renal tubular secretion by cimetidine in man. Br J Clin Pharmacol 1987; 23: 545–51PubMedCrossRefGoogle Scholar
  62. 62.
    Yin OQ, Tomlinson B, Chow MS. Variability in renal clearance of substrates for renal transporters in Chinese subjects. J Clin Pharmacol 2006; 46: 157–63PubMedCrossRefGoogle Scholar
  63. 63.
    Zhang L, Tian Y, Zhang Z, et al. Simultaneous determination of metformin and rosiglitazone in human plasma by liquid chromatography/tandem mass spectrometry with electrospray ionization: application to a pharmacokinetic study. J Chromatog B 2007; 854: 91–8CrossRefGoogle Scholar
  64. 64.
    Ohta KY, Inoue K, Yasujima T, et al. Functional characteristics of two human MATE transporters: kinetics of cimetidine transport and profiles of inhibition by various compounds. J Pharm Pharm Sci 2009; 12: 388–96PubMedGoogle Scholar
  65. 65.
    Xia L, Zhou M, Kalhorn TF, et al. Podocyte-specific expression of organic cation transporter PMAT: implication in puromycin aminonucleoside nephrotoxicity. Am J Physiol Renal Physiol 2009; 296: F1307–13PubMedCrossRefGoogle Scholar
  66. 66.
    Wang ZJ, Yin OQ, Tomlinson B, et al. OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet Genomics 2008; 18: 637–45PubMedCrossRefGoogle Scholar
  67. 67.
    Ogasawara K, Terada T, Motohashi H, et al. Analysis of regulatory polymorphisms in organic ion transporter genes (SLC22A) in the kidney. J Hum Genet 2008; 53: 607–14PubMedCrossRefGoogle Scholar
  68. 68.
    Tzvetkov MV, Vormfelde SV, Balen D, et al. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther 2009; 86(3): 299–306PubMedCrossRefGoogle Scholar
  69. 69.
    Toyama K, Yonezawa A, Tsuda M, et al. Heterozygous variants of multidrug and toxin extrusions (MATE1 and MATE2-K) have little influence on the disposition of metformin in diabetic patients. Pharmacogenet Genomics 2010; 20: 135–8PubMedCrossRefGoogle Scholar
  70. 70.
    Matsushima S, Maeda K, Inoue K, et al. The inhibition of human multidrug and toxin extrusion 1 is involved in the drug-drug interaction caused by cimetidine. Drug Metab Dispos 2009; 37: 555–9PubMedCrossRefGoogle Scholar
  71. 71.
    Meyer zu Schwabedissen HE, Verstuyft C, Kroemer HK, et al. Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol 2010; 298: F997–1005PubMedCrossRefGoogle Scholar
  72. 72.
    Ito S, Kusuhara H, Kuroiwa Y, et al. Potent and specific inhibition of mMate1-mediated efflux of type I organic cations in the liver and kidney by pyrimethamine. J Pharmacol Exp Ther 2010; 333: 341–50PubMedCrossRefGoogle Scholar
  73. 73.
    He YL, Sabo R, Picard F, et al. Study of the pharmacokinetic interaction interaction of vildaglitpin and metformin in patients with type 2 diabetes. Curr Med Res 2009; 25: 1265–72CrossRefGoogle Scholar
  74. 74.
    Di Cicco RA, Allen A, Carr A, et al. Rosiglitazone does not alter the pharmacokinetics of metformin. J Clin Pharmacol 2000; 40: 1280–5PubMedGoogle Scholar
  75. 75.
    Kudolo GB, Wang W, Javors M, et al. The effect of the ingestion of Ginko biloba extract (EGb 761) on the pharmacokinetics of metformin in non-diabetic and type 2 dabetic subjects: a double blind placebo-controlled, crossover study. Clin Nutr 2006; 25: 606–16PubMedCrossRefGoogle Scholar
  76. 76.
    Vaidyanathan S, Maboudian M, Warren V, et al. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects. Curr Med Res Opin 2008; 24: 2313–26PubMedCrossRefGoogle Scholar
  77. 77.
    Jayasagar G, Krishna Kumar M, Chandrasekhar K, et al. Effect of cephalexin on the pharmacokinetics of metformin in healthy human volunteers. Drug Metabol Drug Interact 2002; 19: 41–8PubMedCrossRefGoogle Scholar
  78. 78.
    Zolk O, Solbach TF, Konig J, et al. Structural determinants of inhibitor interaction with the human organic cation transporter OCT2 (SLC22A2). Naunyn Schmiedebergs Arch Pharmacol 2009; 379: 337–48PubMedCrossRefGoogle Scholar
  79. 79.
    Salpeter SR, Greyber E, Pasternak GA, et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010; (4): CD002967PubMedGoogle Scholar
  80. 80.
    Australian Medicines Handbook Pty Ltd. Australian medicines handbook [online]. Available from URL: http://www.amh.net.au/ [Accessed 2010 Dec 14]
  81. 81.
    Howlett HC, Bailey CJ. A risk-benefit assessment of metformin in type 2 diabetes mellitus. Drug Saf 1999; 20: 489–503PubMedCrossRefGoogle Scholar
  82. 82.
    Vasisht KP, Chen SC, Peng Y, et al., editors. Metformin use in diabetes with advanced nephropathy [abstract]. Endo 09; 2009 Jun 10–13; Washington, DCGoogle Scholar
  83. 83.
    Frid A, Sterner GN, Löndahl M, et al. Novel assay of metformin levels in patients with type 2 diabetes mellitus and varying levels of renal function: clinical recommendations. Diabetes Care 2010; 33: 1291–3PubMedCrossRefGoogle Scholar
  84. 84.
    Bodmer M, Meier C, Krahenbuhl S, et al. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. Diabetes Care 2008; 31: 2086–91PubMedCrossRefGoogle Scholar
  85. 85.
    Brady WJ, Carter CT. Metforminoverdose. Am JEmergMed 1997; 15: 107–8PubMedCrossRefGoogle Scholar
  86. 86.
    Guo PY, Storsley LJ, Finkle SN. Severe lactic acidosis treated with prolonged hemodialysis: recovery after massive overdoses of metformin. Semin Dial 2006; 19: 80–3PubMedCrossRefGoogle Scholar
  87. 87.
    Gjedde S, Christiansen A, Pedersen SB, et al. Survival following a metformin overdose of 63 g: a case report. Pharmacol Toxicol 2003; 93: 98–9PubMedCrossRefGoogle Scholar
  88. 88.
    Chang LC, Hung SC, Yang CS. The case: a suicidal woman with delayed high anion gap metabolic acidosis. Kidney Int 2009; 75: 757–8PubMedCrossRefGoogle Scholar
  89. 89.
    Lalau JD, Race JM. Lactic acidosis in metformin-treated patients: prognostic value of arterial lactate levels and plasma metformin concentrations. Drug Saf 1999; 20: 377–84PubMedCrossRefGoogle Scholar
  90. 90.
    Bruijstens LA, van Luin M, Buscher-Jungerhans PM, et al. Reality of severe metformin-induced lactic acidosis in the absence of chronic renal impairment. Neth J Med 2008; 66: 185–90PubMedGoogle Scholar
  91. 91.
    Lalau JD, Race JM. Lactic acidosis in metformin therapy: searching for a link with metformin in reports of ‘metformin-associated lactic acidosi’. Diabetes Obes Metab 2001; 3: 195–201PubMedCrossRefGoogle Scholar
  92. 92.
    Gambineri A, Tomassoni F, Gasparini DI, et al. Organic cation transporter 1 polymorphisms predict the metabolic response to metformin in women with the polycystic ovary syndrome. J Clin Endocrinol Metab 2010; 95: E204–8PubMedCrossRefGoogle Scholar
  93. 93.
    Zhou K, Donnelly LA, Kimber CH, et al. Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study. Diabetes 2009; 58: 1434–9PubMedCrossRefGoogle Scholar
  94. 94.
    Becker ML, Visser LE, van Schaik RH, et al. Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. Pharmacogenomics J 2009; 9: 242–7PubMedCrossRefGoogle Scholar
  95. 95.
    Becker ML, Visser LE, van Schaik RH, et al. Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study. Diabetes 2009; 58: 745–9PubMedCrossRefGoogle Scholar
  96. 96.
    Becker ML, Visser LE, van Schaik RH, et al. Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response. Pharmacogenet Genomics 2010; 20: 38–44PubMedCrossRefGoogle Scholar
  97. 97.
    Jablonski KA, McAteer JB, de Bakker PI, et al. Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program. Diabetes 2010; 59: 2672–81PubMedCrossRefGoogle Scholar
  98. 98.
    Marchetti P, Gregorio F, Benzi L, et al. Diurnal pattern of plasma metformin concentrations and its relation to metabolic effects in type 2 (non-insulin-dependent) diabetic patients. Diabetes Metab 1990; 16: 473–8Google Scholar
  99. 99.
    Duong JK, Greenup LC, Graham GG, et al. Optimising metformin therapy in patients with renal impairment [poster]. 43rd Annual Scientific Meeting of the Australasian Society of Clinical and Experimental Pharmacology and Toxicology; 2009 Nov 29–Dec 2; Sydney (NSW)Google Scholar
  100. 100.
    Hanze E. Pharmacokinetic and pharmacodynamic modelling of metformin in obese patients with type 2 diabetes [MSc thesis]. Brisbane (QLD) and Uppsala: University of Queensland and University of Uppsala, 2006Google Scholar
  101. 101.
    Krentz AJ, Ferner RE, Bailey CJ. Comparative tolerability profiles of oral antidiabetic agents. Drug Saf 1994; 11: 223–41PubMedCrossRefGoogle Scholar
  102. 102.
    Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41PubMedCrossRefGoogle Scholar
  103. 103.
    Hermann LS, Schersten B, Melander A. Antihyperglycaemic efficacy, response prediction and dose-response relations of treatment with metformin and sulphonylurea, alone and in primary combination. Diabet Med 1994; 11: 953–60PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2011

Authors and Affiliations

  • Garry G. Graham
    • 1
  • Jeroen Punt
    • 1
  • Manit Arora
    • 1
  • Richard O. Day
    • 1
  • Matthew P. Doogue
    • 2
  • Janna Duong
    • 1
  • Timothy J. Furlong
    • 3
  • Jerry R. Greenfield
    • 4
  • Louise C. Greenup
    • 1
  • Carl M. Kirkpatrick
    • 5
  • John E. Ray
    • 1
  • Peter Timmins
    • 6
  • Kenneth M. Williams
    • 1
  1. 1.Departments of Pharmacology & Toxicology and Medicine, St Vincent’s Clinical SchoolUniversity of New South WalesSydneyAustralia
  2. 2.Department of Clinical PharmacologyFlinders Medical CentreAdelaideAustralia
  3. 3.Department of NephrologySt Vincent’s HospitalSydneyAustralia
  4. 4.Department of Endocrinology and Diabetes Centre, St Vincent’s Hospital and Diabetes and Obesity Research ProgramGarvan Institute of Medical ResearchSydneyAustralia
  5. 5.School of PharmacyThe University of QueenslandBrisbaneAustralia
  6. 6.Biopharmaceutics Research and DevelopmentBristol-Myers Squibb CompanyMoretonUK

Personalised recommendations